Drug Overview
Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma. Cinqair gained US and EU approvals for use in asthma in an IV formulation in March 2016 and August 2016, respectively. Teva is also developing a subcutaneous formulation of Cinqair, which is in Phase III.
Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma. Cinqair gained US and EU approvals for use in asthma in an IV formulation in March 2016 and August 2016, respectively. Teva is also developing a subcutaneous formulation of Cinqair, which is in Phase III.
Table of Contents
Product ProfilesCinqair: Asthma
List of Figures
Figure 54: Drug assessment summary of Xolair in asthma
Figure 55: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 3: Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26
List of Tables
Table 1: Cinqair drug profile
Table 2: Cinqair pivotal Phase III data in asthma
Table 3: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26
